Porphyrin uptake in lung cancer cells by dynamin-mediated endocytosis: a novel marker of dysregulated endocytosis in cancer. American Society of Cell Biology Annual Meeting, December, 2015

PUBLISHED ON December 25, 2015

Porphyrins are dynamic molecules involved in many biological processes, including oxygen and electron transport. Porphyrins have also been known to incorporate more readily into cancer cells compared to non-cancerous cells, and this property of porphyrins is being explored for diagnostic and therapeutic applications in cancer patients.

San Antonio biotech company secures Chinese patent for cancer-detection test

PUBLISHED ON December 16, 2015

San Antonio Business Journal (December 16, 2015) The People’s Republic of China has awarded a Certificate of Invention Patent to bioAffinity Technologies for its proprietary CyPath® assay, which could have a profound impact on cancer detection globally.

bioAffinity Technologies Announces Patent Award in China

PUBLISHED ON December 14, 2015

SAN ANTONIO, TX (December 14, 2015) bioAffinity Technologies announced the People’s Republic of China awarded a Certificate of Invention Patent for the Company’s proprietary CyPath® assay, a bio-label that preferentially binds to cancer cells and labels them a brilliant crimson red that can be detected and measured by fluorescent imaging.

Porphyrin Uptake in Lung Cancer Cells by Dynamin-Mediated Endocytosis: a Novel Marker of Dysregulated Endocytosis in Cancer

PUBLISHED ON December 14, 2015

The University of Texas Health Science Center San Antonio

bioAffinity Technologies Announces Novel Cancer Bio-label Presented at ASCB Annual Meeting

PUBLISHED ON December 10, 2015

SAN ANTONIO, TX (December 10, 2015) The porphyrin compound used in bioAffinity Technologies’ proprietary CyPath® Lung is a novel marker for endocytosis, new research shows.